Pharmaceutical stocks rose, and a number of pharmaceutical companies in the bio-vaccine sector rose and stopped.

"Pharmaceutical network industry dynamics" August 5, the two stock indexes throughout the day wide swings, including the GEM index performance is stronger, the GEM index rose nearly 1%, the Shanghai index was pulled up after the early morning quickly killed, the afternoon around the red market line near the shock, slightly up 0.17%.
from the current ups and downs data as a whole, pharmaceutical stocks are still a strong sector.
the pharmaceutical sector has always been a good heart for institutions and foreign capital and other large funds, now with the popularity of value investment in A-shares, more and more funds gradually participate in the investment of pharmaceutical stocks.
especially this year's particularity, the vaccine plate recent momentum such as Hong, the leader Boao innovation is to receive 6 boards.
Pharmaceutical stocks rose, the bio-vaccine sector a number of pharmaceutical companies up and down note that, according to the relevant data, as of the close of August 4, all the concept sectors of the year, the concept of biological vaccine rose the first, up 128.48 percent, is the current one of the few to double the concept.
, in addition to Boao innovation, Watson biology, revival medicine have also appeared in the board.
Boao Innovations august 5, Boao Innovations today opened at a low of 11.3 yuan per share.
, however, between 10:39 a.m. and 10:45 a.m., the company's share price staged a six-minute straight rally, which was followed by a halt to the rally to close at 13.31 yuan per share.
fact, boao innovation surge, can not be separated from a series of good news.
As early as July 24, the company announced that the holding company Zhongke Bio and Chengdu Bootek signed a "project cooperation contract" in January 2020, jointly declared freeze-dried human rabies vaccine (serum-free Vero cells) products.
the product recently received approval from the State Drug Administration to issue a "Drug Clinical Trial Approval Notice."
news of the vaccine came out, Boao Innovations rose 9.96 percent on July 24 to close at 8.06 yuan per share.
And then, Boao innovation and successive disclosure, holding subsidiary Hebei Da'an research and development of static injection human immunoglobulin (pH4) products, and human clotting enzyme progeny complex recently received the Approval of the State Drug Administration issued the "Drug Registration Certificate."
in a series of good, Boao innovative share price "boiling" is also a matter of course.
Watson Bio-Watson bio-main business for vaccine product development, production, sales, according to sky-eye data show that Watson Bio has soared 180% during the year, now a total market value of more than 140 billion yuan.
on August 5, Watson Bio rose again, with an offer of 87.67 yuan, or 5.06 percent, at 10:33 a.m., with 304,894 lots traded, with a turnover of 2.575 billion yuan and a turnover rate of 2.06 percent.
industry analysts believe that since this year, Watson Bio's share price continued to rise, mainly due to its subsidiary Yuxi Watson Biotechnology Co., Ltd. developed a 13-price pneumococcal polysaccharide binding vaccine, has received the Approval of the State Drug Administration issued a "drug registration certificate."
it is learned that Watson bio-independent research and development of PCV13 is the world's second, China's first 13-price pneumococcal binding vaccine.
obtained the "Drug Registration Approval", which means that the first domestic PCV13 is about to "shine on the scene", which is an important milestone in the development of pneumonia vaccine in China, but also the main growth point of Watson Bio's performance in the future.
recent, Fosun Pharma's rise and fall, turnover is expected to make history.
July 15th, the 16th staged a day of ups and downs and downs of the surprise drama.
is rare for Fosun Pharma, a large-cap stock with a market capitalisation of hundreds of billions.
It is worth noting that on August 3, Fosun Pharma announced that the anti-tuberculosis drug ethylamine butanol tablets through generic consistency evaluation, affected by this news, its share price continued to rise, as of 10:25 a.m. on the same day, up 3.38 percent, the offer of HK$39.75, turnover of 274 million.
August 6th, at 9:34 a.m., Fosun Pharma's share price surged to a 12-month high.
the industry believes that by the Indian company listing approval process, Fuhong Hanxuan has been approved to list on the Board, Fosun Kate's Cart will not be unexpectedly approved this year and other good news impact, the future market value of Fosun Pharma will also break new highs.
.